Progressing new bioconjugates or antibody-drug conjugates (ADC) forward from discovery to the investigational new drug (IND) submission stage can be a challenging and cumbersome process. The complexity of drug design as well as the extensive technical, safety, stability and scalability challenges — especially when it comes to the linker — makes it incredibly difficult for developers to navigate the development pathway with speed and ease while still ensuring an effective, high-quality product.

In this webinar, the featured experts will explore key considerations when designing and developing a bioconjugate or ADC and the impactful role that linker technologies play in accelerating and de-risking the development process to the IND submission stage. Based on case studies, the experts will also provide insights into topics such as oligonucleotide design and development, ADC to good manufacturing practice (GMP) requirements and the overall application of developability for ADC lead candidate selection.

Register for this webinar today to gain insights into designing and developing a bioconjugate or ADC and the impactful role of linker technologies in accelerating and de-risking the development process.

Keywords:

Speakers

Dr. Petra Dieterich, SVP and Scientific Leader, Abzena

Dr. Petra Dieterich holds a PhD in synthetic organic chemistry and an MBA from Imperial College London. She has more than three decades’ experience working in drug development with a focus on CMC activities and has wide-ranging experience working in a CRO environment and leading projects for biotech companies in the development of APIs for clinical trials and commercial use.

Message Presenter

Dr. Nicolas Camper, Sr. Director of Bioconjugation Chemistry, Abzena

Dr. Nicolas Camper holds a PhD from Queen’s University Belfast on the synthesis of bisphosphonate conjugates to antibody fragments for applications in oncology. Nicholas has experience in bioconjugation, protein engineering, protein expression in bacterial and mammalian systems as well as synthetic chemistry.

Message Presenter

Who Should Attend?

This webinar will appeal to the following:

Biopharma CMC
Biopharma method development
Biopharma process development
Biophysical Scientists in government and academia

What You Will Learn

The attendees will learn about:

How to maximize payload potential via site-specific conjugation
How to achieve a more uniform drug antibody ratio (DAR) profile and stable attachment
How to optimize the pharmacokinetics (PK) profile
How Abzena’s unique ThioBridge conjugation technology improves stability, potency and efficacy

Xtalks Partner

Abzena

Abzena is as committed to success as you are. We have the capabilities, capacity and knowledge to move your asset forward as carefully and quickly as possible.

Our seasoned professionals offer the kind of personalized service and flexible working relationship that your demanding, time-sensitive programs deserve. We’re not afraid to question assumptions, and not shy about presenting new and better ideas.

And then, we deliver.

With research, development, and cGMP facilities across locations in San Diego, CA, Bristol, PA, and Cambridge, UK, Abzena is fully prepared to move your bioconjugate and biologics programs forward at every step in the process.